080062: Adaptation of Human (Pro)renin Receptor for Drug Screening
Case ID:
TEC2008-0062
Web Published:
7/21/2014
Description:
The
recent discovery of (pro)renin receptor, PRR, may have significant implications
for intracellular signaling. Moreover, animal studies of PRR have shown that its
gene knockout results in lifelessness. Thus, an understanding of PRR could lead
to one or more valuable therapies. PRR is also involved in the regulation of
blood pressure at a “localized” level. Renin bound to PRR appears to be more
active than the free enzyme, and prorenin bound to PRR is also activated. The
ability to effect changes in PRR could result in a new, fourth approach to
anti-hypertensive therapy.
Michigan
State University’s technology has demonstrated the formation of the prorenin/PRR
complex in vitro and that recombinant human PRR can activate prorenin. The
invention includes PRR’s 3D structure for SAR analysis, its functions, and the
modification of PRR for use in high-throughput screening. Researchers have
demonstrated the formation of a prorenin/PRR complex in vitro and that the
recombinant human PRR can activate prorenin. Depending on the cell type, ELISA
array assays can be set up to determine if prorenin is activated and how
intracellular signaling is elicited by PPR. Compounds can then be screened to
see if prorenin activation or intracellular signaling is blocked. Versatile
implementations would allow the assay system to be optimized for the most in
vivo-like response.
Benefits
There are
several treatments that reduce systemic blood pressure. However, tissue damage
continues even after successful lowering of blood pressure with contemporary
therapeutics. Recent research has strongly suggested that local, or “internal,”
blood pressure control in the vasculature and tissues is as important as the
control of systemic blood pressure. Currently, there is no commercial treatment
for localized blood pressure. This invention could facilitate discovery of the
following:
* Diverse
pathways critical to sustaining life based on intracellular signaling via PPR.
* Ligands
for anti-hypertensive therapeutics for a new BP regulatory system based on PRR
functionality in targeted tissues.
Applications
Applications include:
*
Pharmaceutical research in novel intracellular signaling
*
Anti-hypertensive therapeutics
IP Protection
Status
Patent
pending
Patent Information:
App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |
For Information, Contact:
Randy Ramharack
Technology Manager
Michigan State University - Test
517-355-2186
ramharac@msu.edu